Good morning. My name is Andrea and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Inc's 2022 Second Quarter Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead.
Thank you very much. Good morning and welcome to Novanta's second quarter 2022 earnings conference call. I am Ray Nash, Corporate Finance Leader of Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra, and our Chief Financial Officer, Robert Buckley. If you've not received a copy of our earnings press release issued today, you may obtain it from the investor relations section of our website at www.novanta.com. Please note this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today, and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements.
These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. You should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release.
To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the investor relations section of our website after this call. I am now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.
Thank you, Ray. Good morning, everybody and thanks for joining our call. Novanta achieved impressive results in the second quarter of 2022. We delivered another quarter of terrific financial performance with double-digit growth in revenue, bookings, adjusted EBITDA, and adjusted EPS. We ended the quarter with another record level of backlog. We continue to see very robust demands from our customers in the medical and advanced industrial markets we serve. Novanta's portfolio is well-positioned in medical and advanced industry applications with long-term secular tailwinds such as robotics and automation, healthcare productivity, and precision medicine. We continue to invest for growth in a disciplined manner to strengthen our commercial teams, our innovation pipeline, and manufacturing capacity to capitalize on these tailwinds.
In the second quarter, the company delivered $215 million in revenue, representing 29% year-over-year revenue growth on a reported basis, and 13% growth on an organic basis, and up 5% on a sequential basis. Our operating profit in the second quarter was fantastic, with adjusted EBITDA of $45 million, up 22% year-over-year, and adjusted diluted earnings per share of $0.78, up 26% versus prior year. We saw strong demand and healthy orders across all our segments and in many of our applications, with each segment having solid book-to-bill in the quarter. In the second quarter, our overall book-to-bill was 1.34, with year-over-year bookings growth of 25% versus the second quarter of 2021.
We ended the quarter with a record backlog of $653 million, up 11% sequentially as demand continued to be gated by supply constraints. The excellent year-to-date financial performance gives us confidence to raise our financial guidance for the full year, which Robert will cover in detail in a few minutes. We're doing this in the face of a significant amount of uncertainty and macroeconomic and supply chain challenges. We feel that where we play and how we win is an important part of our success. We build and grow quality businesses with proprietary IP in attractive secular growth markets with vibrant culture and great people. I just wanna say how proud I am of our teams around the world and how extremely pleased we are with the team's exceptional operating performance using the Novanta Growth System tools in this uncertain environment.
Now let's turn to what we're seeing in our markets, where we see ongoing strength in multiple application areas. In the second quarter, our sales to advanced industrial markets saw 42% growth year-over-year and 5% growth sequentially. We continue to experience higher demand in automation and robotics markets, and specifically factory automation, battery and electric vehicle production, EUV and increased adoption of automation-enabling technologies. We believe that the penetration of robotic and auto-automation applications is still relatively low, with adoption increasing due to multiple drivers such as increased productivity, higher robot utility, onshoring, and labor shortages. Turning to our medical end market. For the second quarter of 2022, sales to medical applications grew 16% versus the second quarter of 2021, and 6% growth sequentially.
During the quarter, we saw very strong orders and shipments to many of our medical OEM customers, with particular strength in surgical robotics, DNA sequencing, and medical consumables for minimally invasive surgery, all of which saw strong double-digit growth in sales year-over-year. We believe that the penetration rate of these technologies is still low, with an attractive long-term growth trajectory and with Novanta content steadily increasing. It was also encouraging to see the strength in medical consumables, which supports a broader improvement in elective surgical procedures. We expect that medical sales and minimally invasive surgery procedures will continue to rebound gradually throughout 2022 as hospitals are battling staff shortages. Our longer-term outlook on the minimally invasive surgery market remains bullish, particularly with our playbook of expanding share with our unique product offering of integrated smoke evacuation insufflators.
From a regional perspective, we saw strong demand across all our major geographies in the second quarter. We saw 27% year-over-year revenue growth in China, helped by our ATI acquisition, which saw strong electric vehicle production and robotic demand. Our China revenue, excluding acquisitions, was roughly flat year-over-year, which was remarkable given significant COVID disruptions and lockdowns in China and continued supply constraints. Our backlog and demand in China is very strong, helped by increased exposure to electric vehicle production, micromachining, and electric vehicle battery production. Moving on to other regions. Sales in Europe grew 20%, and sales in the United States grew 46% year-over-year. Now, let me touch on some of Novanta's strategic growth metrics. As a reminder, right now, these metrics exclude any impact from our ATI and IMS acquisitions.
For the second quarter vitality index, which is revenue from new products launched in the last four years, continues to be healthy at above 25% of sales, with year-over-year NPI revenues up low double digits versus last year. Despite some modest delays in some of our programs, which we've spoken to previously, we see other programs that are progressing nicely, and our new product pipeline for 2022 and beyond remains very healthy. We continue to invest in R&D with discipline in order to capture the many mid and long-term opportunities with differentiated offerings in high-growth markets. Moving on, in the second quarter, design wins for the overall company increased more than 20% versus the prior year.
We saw strong design wins in the majority of our businesses, and we are excited about the platforms were winning in attractive high-growth applications such as surgical robotics, laser additive manufacturing, micromachining, EUV, and electric vehicle battery welding. Before wrapping up, I'd like to give you a brief update on Novanta's acquisition and integration activities. Our ATI and IMS businesses saw strong performance for sales and bookings in the second quarter. We continue to be very pleased with their contribution and strategic fit to Novanta and are very pleased to see the way their teams are collaborating with our other businesses and elevating the capabilities of the entire organization. As for the rest of our M&A pipeline, acquisitions continue to be the primary focus of Novanta's capital deployment. We continue to work on a very active pipeline of opportunities.
In summary, despite the significant short-term supply chain challenges and the uncertainty of the macroeconomic environment, we feel excellent about our second quarter results, and we continue to see strength in the second half of the year. We believe Novanta's long-term strategic positioning is extremely strong. We continue to broaden our exposure to medical and industrial applications that have long-term secular growth trends, such as robotics and automation, healthcare productivity, and precision medicine. With that, I'll turn the call over to Robert to provide more details on our operations and financial performance. Robert?
Thank you, Matthijs, and good morning, everyone. Our second quarter non-GAAP adjusted gross profit was $98.8 million or 46% adjusted gross margin, compared to $76.9 million or 40% gross margin in the second quarter of 2021. For the quarter, adjusted gross margins were flat year-over-year and sequentially. Considering the environment of high inflation, supply chain shortages, and currency exchange volatility, we feel quite good about this outcome. We continue to experience supply chain shortages and inflationary pressures with semiconductor parts, but we're also seeing solid productivity from the deployment of the Novanta Growth System, and we are experiencing the impact of our pricing initiatives helping to offset the inflation. Moving on, the second quarter R&D expenses were $21.6 million or roughly 10% of sales. Second quarter SG&A expenses were $40.5 million or 18.8% of sales.
The sequential increases in operating expenses, which were in line with prior guidance, were the result of the impact of variable compensation programs as well as planned R&D investments. Adjusted EBITDA was approximately $45 million in the second quarter of 2022 or a 21% adjusted EBITDA margin. Our adjusted EBITDA performance beat our expectations and our previously issued guidance. On the tax front, our non-GAAP tax rate in the second quarter of 2022 was 18%. This differed from the statutory rate driven mainly by jurisdictional mix of income. Our non-GAAP adjusted earnings per share was $0.78 in the quarter, compared to $0.62 in the second quarter of 2021, an increase of 26% year-over-year. The strong increase in adjusted EPS was achieved despite the higher financing costs and higher tax rate.
Second quarter operating cash flow was approximately $24 million, which was in line with our expectations. The second quarter cash flow continued to be impacted by anticipated increases in working capital, which was mostly driven by higher inventory purchases to mitigate some of the supply chain disruptions. Cash flow was negatively impacted by $2.5 million in higher cash taxes related to a change in U.S. tax law, which impacts the deductibility of R&D costs. Finally, in the second quarter, we purchased approximately $10 million worth of Novanta shares at an average price of $119 a share when the stock weakened due to macroeconomic conditions. We ended the quarter with gross debt of $413 million and gross leverage ratio of 2.4 x. Our net debt was $312 million.
I'll now turn to update about the performance of the operating segments. First, I'll start with the Precision Motion segment. This segment experienced 93% year-over-year revenue growth in the quarter. Reported growth was heavily impacted by the ATI and IMS acquisitions. In the second quarter, these businesses contributed approximately $35 million of sales, which was in line with our expectations. These businesses continue to perform very well. Their integration is proceeding on schedule, and they continue to offer very exciting near-term and long-term growth opportunities for Novanta. Excluding the acquisitions, Precision Motion still grew 9% year-over-year. The overall book-to-bill ratio in this segment was 1.1 in the quarter. Excluding the impact of ATI and IMS, the Precision Motion new product revenue grew 40% year-over-year and was over 25% of total sales for the segment.
Design wins for the second quarter were up double-digit versus the prior year. Adjusted gross margins for the segment came in around 50%, which was down year-over-year, but in line with the expectations and came as a result of some dilution from the new acquisitions. This segment continues to show a very strong impact from deploying the Novanta Growth System to structurally improve gross margins. Turning to our Vision segment. This segment predominantly serves the medical end market and saw revenue growth of 3% year-over-year, which was slightly better than our expectations. As we said in the last call, the volume of elective surgical procedures has gradually started to return, which helped sales performance in our minimally invasive surgical business.
Offsetting this was the supply headwind in our JADAK business, which experienced significant part shortages that temporarily caused a decline in their sales, but not in their demand. The net impact of these dynamics was modest growth that we saw in this segment. Although the supply shortages at JADAK are resolving, we expect these dynamics to persist for at least another quarter. The Vision segment saw a healthy book-to-bill of 1.32, with bookings increased 18% year-over-year. The vitality index in this segment remained around 30% of sales. Design win activity in the segment increased strong double digits year-over-year in the quarter as the segment continues to deliver strong customer wins in attractive application areas. Finally, turning to the Photonics segment for the second quarter of 2022. Our revenue was up 11% year-over-year.
This segment continues to experience strong customer demand in the advanced industrial applications and DNA sequencing. The book-to-bill in this segment was a fantastic 1.63 in the second quarter, with bookings growing 25% year-over-year. The excellent results demonstrate the sustained demand we see in our beam steering and light engine products. Although the production move of our Taunton, U.K., facility is now fully complete, resulting in more supply of optics for our products. Recently, one of our critical electronics vendor experienced a fire in their factory, reducing our supply of parts. However, we expect to mitigate the majority of electronic parts shortfall due to the fire and continue to show strong growth in the third quarter. I could not be more impressed with our supply chain and manufacturing team's performance, demonstrated by the extraordinary efforts to overcome yet another challenge.
Within the Photonics, new product revenue stayed strong at 25% of sales in the second quarter. Design wins year-to-date are up double digits year-over-year, driven by excellent platform wins in applications such as laser additive manufacturing, micromachining, and EUV lithography. The Photonics segment experienced adjusted gross margins of approximately 46%, which was down year-over-year, but in line with our expectations. Gross margins experienced temporary pressure from the Taunton move and our electronics vendor who had a fire. We expect gross margins in this segment to continue to expand in the second half of the year, both sequentially and year-over-year as we recover from these issues. Turning now to guidance. Overall, we expect macroeconomic environment to continue to follow the prevailing trends. We expect inflation, supply shortages, particularly around electronics, and volatility with foreign currencies to continue.
Clearly, there are signs of economic and manufacturing activity slowing, particularly in China and Europe, as well as some moderation in certain parts of the semiconductor market. Despite all these factors, Novanta has a healthy outlook for the remainder of the year, supported by our record backlog and the ongoing excellent execution of our committed teams. Starting with revenue guidance for the third quarter of 2022. As we stand here today, we expect GAAP revenue in the range of $214 million-$216 million, which will imply revenue growth of 20%-22% year-over-year.
The overall range in guidance is driven by both electronic part shortages and foreign exchange headwinds and not underlying demand. On a segment level in the third quarter, we expect Photonics segment to be largely flat sequentially on a dollar basis, representing organic growth of greater than 25% year-over-year. Customer demand remains very high in this segment and hence this business is governed solely by electronic part shortages. The Vision segment is expected to be up slightly on a dollar basis in the third quarter, similar, seeing similar dynamics as we experienced in the second quarter. The Minimally Invasive Surgery business line is expected to continue to see growth in medical consumables due to the recovery of elective surgical procedures, whereas our JADAK business line continues to improve from its parts availability issues, albeit slowly.
Finally, our Precision Motion segment is expected to be down slightly on a sequential basis due to seasonality with the ATI business line, but up significantly on a year-over-year basis. We continue to see strong organic growth in our Celera Motion business line and the ATI business line despite significant part shortages in both businesses. For the full year of 2022, our strong first half and continued strong backlog gives us confidence to raise our guidance. We now expect GAAP revenue in the range of $848 million-$852 million, which implies revenue growth of 20%-21% year-over-year. Moving on to overall Novanta's adjusted gross margins, we expect gross margins in the third quarter to be approximately 46%, which would be robust margin expansion versus prior year.
We expect third quarter gross margins to see similar dynamics sequentially, although there may be some segment-by-segment variations as teams tackle unique impacts from the multitude of challenges related to supply chains. For the full year of 2022, we expect Novanta's adjusted gross margins to be approximately 46%, which represents close to 100 basis points of expansion year-over-year. In this challenging environment, expanding margins would be a huge accomplishment. Thanks to our continued focus on new products, which are launching with gross margins above the company average, as well as significant investments and progress with the Novanta Growth System across our business units and a pricing strategy focused on sharing the inflationary pressures and supply chain disruptions with our customers. We feel confident we are on a path of continued and sustained gross margin expansion this year and the next.
Turning to R&D and SG&A expenses, which were up $62 million in the second quarter, are expected to be approximately $63 million-$64 million in the third quarter, which is higher mainly as a consequence of recent acquisitions and higher variable compensation and timing related to investments in new product development. We continue to invest in R&D even with the macroeconomic uncertainty, because of our confidence in near-term customer opportunities we are pursuing and the expected launch cycles of our customers' new products. Depreciation expense was $3 million in the second quarter and should be very similar in the third quarter. Stock compensation expense, which was $5 million in the second quarter, will be similar in the third quarter. For adjusted EBITDA for the third quarter of 2022, we expect a range of $43.5 million-$45.5 million.
For the full year, we now expect adjusted EBITDA in the range of $177 million-$180 million, higher than previously issued guidance. Interest expense, which was $3 million in the second quarter, will be approximately $4 million in the third quarter, driven by rising interest rates and higher debt balances. We expect non-GAAP tax rate to be approximately 16% in the third quarter, absent significant changes in the jurisdictional mix of income or other variability in our eligible tax benefits. Diluted weighted average shares outstanding will be approximately 36 million shares. For adjusted diluted earnings per share, we expect a range of $0.71-$0.76 for the third quarter. For the full year, we now expect adjusted diluted earnings per share to be approximately $2.95-$3.02.
Finally, we expect operating cash flows to improve sequentially in the third quarter versus the second quarter as we stabilize our inventory buys. Also of note, in July, we closed the earn out to shareholders of ATI, resulting in an additional payment of $45 million for a total purchase price of $214 million. We intend to finance this with both cash on-hand and our credit facility. As always, this guidance does not assume any significant changes to foreign exchange rates. However, it's worth noting that the currency markets have been very volatile recently, and this has impacted the second quarter results, including material impact on our reported revenue growth and cash flow. Given the continued swings in currency, exchange rates will likely impact our growth in the third quarter at a similar order of magnitude and this is factored into our guidance.
In summary, Novanta's performance in the second quarter of 2022 was excellent. We saw double-digit growth in sales, bookings, adjusted EBITDA and adjusted earnings per share. The company is seeing strong demand across its applications and markets and we hit another new record high for sales, order backlog, and also our adjusted EBITDA. Our teams continue to impress with new innovations as well as their ability to help the company manage through difficult supply chain challenges and COVID lockdowns. We also continue to see below market labor attrition rates and we are seeing great success at attracting top talent.
We continue to deliver strong financial results with a very solid full year outlook, despite some fairly significant challenges with global supply chains, semiconductor shortages, inflation, China COVID lockdowns, war in Ukraine, currency fluctuations, some slowdown in the microelectronics and general macro, macroeconomic uncertainty. We remain very excited and motivated about our ability to serve our top customers in the medical and advanced industrial end markets and the innovation pipeline we are developing in partnership with our customers. We remain very grateful for the outstanding performance of our employees and their tireless efforts to help us be successful in a very challenging environment. We look forward to continuing to deliver on our commitments to our employees, our customers, and our shareholders. This concludes the prepared remarks. We're now opening the call up for questions.
We will now begin the question-and-answer session. To ask a question, you may press star then one on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the key. To withdraw your question, please press star then two. Our first question will come from Lee Jagoda of CJS Securities. Please go ahead.
Hey, good morning.
Good morning, Lee.
Just starting with the sequential increase in backlog, can you kind of parse out how much of that is volume from existing OEM products that your customers are just trying to get out the door, you know, versus potentially some initial sell-in for some of the new products in the pipeline? To the extent it's any of the latter, is there a quarter, you know, one quarter, two quarter, three quarters out from now where you expect that backlog to release? Or is it really just supply chain constraints holding everything back?
Yeah, Lee, this is Matthijs. It's primarily supply chain constraints holding the backlog back. With demand just outstripping our ability to supply and, you know, despite all that, we delivered very strong results. Let me start by saying that. The other question we haven't really disclosed the split in our sequential backlog and kind of existing customers and new opportunities. But it's fair to say that as we continue to report on design wins that are incremental to our business, right? It will be a mix. And of course, also the increase, let's say exposure over business to high-growth applications. It's being both in the right spot, which then drives the existing business to move faster, as well as winning gradually new business and increasing content in those high-growth markets.
Got it. I think I know the answer to this question, but I have to ask it anyway. In terms of your customers' order patterns, I assume we're not seeing, you know, evidence of safety stock or over ordering, and it's just ordering to demand, and you can see that in their inventories.
That's right. I mean, we do not see much evidence of over ordering, quite frankly. Many of our customers, you know, have given us feedback that they're kind of hand to mouth, quite frankly, with their suppliers, including us. And they're shipping all finished units as soon as they can complete them. Now, of course, we do have less visibility what happens further down the chain, and we're watching that closely. But again, at this moment, we do not see much evidence of over ordering. Overall, we have a large backlog, and we cannot keep up with the demand. Yeah, our focus is quite frankly reducing that pass-through backlog to our customers because they really desperately need our products.
Got it. One more for me, and I'll hop back in the queue here. Just, I know you had mentioned you're seeing an uptick in the WOM consumables just driven by elective procedures. What needs to happen to kind of see or start to see an uptick in the equipment side? When do you see that kind of playing out?
Yeah, I mean, that's typically the logical sequence. The procedures need to go up first and that typically will be followed by capital purchases as hospitals need to bring more capacity online. We do see a healthy hospital capital spend environment. I mean, our customers are reporting on that as well. It will be the gradual logical next step to follow. I think we're very encouraged by what we see happening and what we expect it to happen is a sequential increase and gradual rebound of the elective procedure rates, which we expect to continue to progress in the second half of this year.
Just to be clear, I mean, the big backlog you have here. If I look at the WOM equipment, which should be an important growth driver over the next two, three years, I would assume that piece is under-indexed versus all the rest of the stuff in the current backlog, just because we haven't seen those orders yet.
That's right. So again, we expect that demand will continue to build gradually in the foreseeable future. But again, if you look, you know, short, mid, long term, as we commented in our prepared remarks, we feel very good about the future of that business as we're gaining share with our smoke evacuation insufflator, both in the laparoscopy as well as robotic surgery markets, and we're also expanding share in pumps for arthroscopy. So all that makes for a very exciting future of that business. What you're seeing right now is hospitals just battling through staff shortages, which we expect over time will resolve itself.
Got it. That all sounds great. Thanks very much, guys.
Sure.
The next question comes from Brian Drab of William Blair. Please go ahead.
Hi. Good morning. Thanks for taking my questions. First, I'm just thinking back to the back half of 2019 when, you know, there were challenges in China. Europe business slowed down. Germany was a challenge for you. Can you talk just a little bit about, you know, comparing, you know, that market environment to what you're seeing now in China and Europe and a lot of differences there. I'd just love to hear you talk about that and how that, you know, influences how you're viewing the second half of 2022.
Yeah, I mean, it's hard to compare quite frankly, but of course, when you put yourself in the second half of 2019, we just had massive trade wars and uncertainty on where, you know, trade tariffs would land and therefore basically people stopping investing, right? That had impact in multiple end markets. Right now, what we're seeing is we're emerging out of the pandemic and, you know, in areas like automation and robotics, where there are secular growth trends that are accelerated, that were there already, but they're accelerating, call it, post-pandemic. We continue to see demand for our medical and DNA sequencing products that also are kind of entering into the next phase of their adoption.
We feel that quite frankly, where we've put our business, you know, including acquisitions, we have higher exposure to markets that have, you know, accelerating sequential tailwinds versus where we were in 2019. The other thing that I would say is that we have a higher, you know, percentage of new products that are coming to market. In 2019, if you recall, yeah, we just did some technology acquisitions, but we're now seeing the impact of the product pipeline gradually starting to appear, you know, the latter part of this year in 2023. I would just say, yeah, we're on our front feet, so to speak, dealing with the challenges, you know, head on and being in the right spot.
Where we are and where we play and how we win is really essential. Now, of course, what is maybe similar, and we're not naive, is of course there are, you know, signs of slowdown in some parts of the semiconductor market. Of course, everybody's reading the newspapers about the uncertainty, and of course, we're watching that very, you know, very carefully. But what we can do is of course place our business in the right spots so we can ultimately serve and thrive through what will sure be some additional challenges coming our way in the future.
Got it. Thank you. Can you comment on where you are in the insourcing of the WOM consumables? You still on target for getting the margin expansion there?
Yeah. First, I would say that the in-house manufacturing facilities have done an excellent job at expanding margins and continuing to bring more and more volume into the facility. Because of the way their manufacturing footprint works, you know, getting that volume in is really what's key. Pull it out of our contract manufacturers and bring it in-house. That allows us to better leverage the fixed cost structure that we have there and thereby expand the margin profile. We are simultaneously pursuing some opportunities that are external in nature, and we have a couple different avenues there that we are continuing to work. We feel pretty good that at least one of those will come to fruition relatively soon, and then that will enable us to start bringing even additional product in-house to expand the margins.
At this stage, I think we feel pretty good that there's enough options in front of us that we can start to continue to bring product in-house and expand the margins.
Okay. Thanks very much. I'll pass it on. Thanks.
Thanks, Brian.
The next question comes from Rob Mason of Baird. Please go ahead.
Yes. Good morning. I wanted to go back to, I guess, the question around the backlog. Understanding that your customers may be somewhat hand-to-mouth currently. Is it fair to assume there are some inventory stocking orders, you know, within your backlog, the $653 million? I'm curious if there is any way to give us a percentage of what you would think would be shippable next 12 months absent any kind of supply chain constraints?
You know, most of it is shippable, almost all, well, all of it is shippable in the next 12 months. It's just, it's all being held back with the supply chain constraints themselves, right? There's nothing in there. We don't have any backlog that's countable, and we don't have backlog that's scheduled out greater than a year, being recorded in that number. That's all, you know, 12 months kind of demand flows. It is fair to say that there's some, you know, requests to try to build safety stocks there. We're nowhere near those levels of delivery, and so we're not able to do that. We're more in trying to prevent line downs at our customers and their manufacturing processes than we are about building stock.
If we were to estimate it, you know, I'm sure about 20% of it is definitely tied to stocking, because they don't really have anything whatsoever on their shelves. You know, we're nowhere near the delivery of that.
Yeah.
It does provide us, at least as we look at 2022, it provides us with some confidence in that the revenue numbers should be relatively firm regardless of some macroeconomic conditions.
Yeah. The other thing that I would say, Rob, is just that we do expect kind of our bookings and our book-to-bill to normalize, right? Because I do think the backlog represents, you know, very solid coverage for our customers. We need to deliver on that backlog. Again, we expect book-to-bill and bookings to normalize from here onwards.
Mm-hmm. Okay. Understood. You mentioned price a couple of times just perhaps getting a little bit better traction as that works through the backlog as well. Could you just update us where you think you are currently on a price-cost metric, you know, positive, negative or just where we sit currently?
Yeah. I think our philosophy has always been one that, you know, we're leaning in hard on our Novanta Growth System, which is about driving material productivity and labor productivity in our manufacturing facilities, and then coupling that with a pricing strategy that focuses on sharing some of the inflationary pressures. We have not taken the stance that our customers really have, where they've dramatically raised price in an effort to get margin expansion on top of the inflationary pressures that they have. We have not taken that stance. What we've really done is said, "Okay, the Novanta Growth System is gonna drive X amount of productivity. Pricing's going to drive Y amount, and the combination of those two things will allow us to expand our...
Will allow us to at least neutralize the inflationary pressures, and then the introduction of new products at higher gross margins will allow us to expand those gross margins further. Right? As a net, you're seeing that in the results. First half of the year, you know, we have the 46% gross margins. If we look at the back half and the full year, we're gonna drive gross margin expansion 100 basis points. That's a combination of those activities. Novanta Growth System, a pricing strategy that focuses on sharing some of that cost, new product introductions, and then frankly, driving some of the consumable in-house.
Sure. Okay. Last question I had was, you know, obviously a lot of uncertainty, particularly in Europe, and in particular in and around their energy situation. Germany, you know, seems to be ground zero for that concern it seems like. Given your facility there, I'm just curious how you're approaching that dynamic as we go into the back half of the year and into early next year, what, you know, perhaps you can do to make sure that you've insulated yourself, protected yourself against any kind of interruptions.
Yep
That may come down that way.
Yeah. It's, you know, it's a great question. What happens if the grid goes down is not an easy thing to mitigate. You know, let's presume that there's, you know, some energy production based upon, you know, what they can get in. I think we've taken a number of actions with everything from building in backup generation to reducing our overall energy consumption. Our facility in Germany is ISO 14001 and 45001. It is probably leading the way from an ESG perspective, so they continue to look at ways to reduce their energy consumption. We have also built in some redundancy into our heating systems, and so we can pivot to a multitude of different fuel sources depending upon where the shortages might lie.
If there's a shortage of natural gas, we can pivot to oil. If there's a shortage of oil, we can pivot again. There's a multitude of different angles that we've invested in to try to add that redundancy and that robustness. We're also simultaneously trying to build, as you know, or acquire additional capacity, vis-a-vis, you know, an acquisition strategy. There's a number of different tactics that we are taking to try to increase that redundancy in that facility.
Very good. Thank you.
The next question comes from Andrew Buscaglia of Berenberg. Please go ahead.
Good morning.
Good morning.
I was hoping to focus on Precision Motion for a bit. That's growing organically very strong on a pretty tough comp, much better than I was expecting. Now you have this M&A that's gonna roll into your core growth, you know, kind of starting next quarter, but definitely in Q4. I'm looking out, and it's hard to, you know, you talked a little bit about the cyclical versus secular in some of your businesses. It's hard to, you know, determine what is a long-term growth rate for this kind of a, you know, sort of new segment as we exit the year. Can you help us, you know, kind of think about that and what are the puts and takes going forward?
We've always kind of said that the overall end markets of which we participate in are this 5%-7% organic growth profile, and that as a consequence of some of the new things that we're doing, the innovation, the design wins, you know, new product introductions and whatnot, we've been driving that kind of higher single-digit organic growth contribution. Obviously, we've been outperforming that in a number of different areas of this environment, but structurally speaking, you know, those tend to be where the end markets flow. I would say cyclicality wouldn't impact the kind of long-term growth expectations of an end market participation. The ATI business does have a little bit more cyclicality than most of our other businesses. It tends to have a weaker Q3 than Q4.
That's just because of the, you know, the upgrade cycles and investment cycles associated with some of the end markets in which it participates. Generally speaking, that business performs relatively well. We had guided when we acquired the business that it was certainly participating in that high single digit type of end market, arguably in this environment, like kind of low double digit. The overall motion segment itself tends to be a higher growth area as well, so kind of a lower double digit. It's just, you know, we have to just be realistic here that the overall portfolio here is one of diversification. What we try to do is diversify out the risk elements and volatility and cyclical changes and macroeconomic, you know, differences between businesses and whatnot to drive that sustained organic growth overall. We don't.
We run the business very much like a portfolio manager would run their portfolio-
Mm-hmm
of stocks. You know, we do very similar things in how we invest in our end markets, in our application areas, in our business units to drive a more sustained organic growth profile for the company.
I think just to add to that, it's important to repeat what the end market exposure really is, because then you can kind of get a guess for how good we feel about this. Obviously, very strong exposure to automation and robotics, surgical robotics, increasing exposure also with the ATI acquisition, electric vehicle production, which is going through a super cycle, EUV lithography, which is you know a semiconductor market, but which is also going through a super cycle, e-commerce warehouse and logistics automation in general. This segment also has the highest semiconductor exposure, so you can kind of expect, as a result, a little bit more volatility from that. Within that market, we are, as stated, geared more towards the less cyclical parts of the semiconductor market, for example, EUV.
Many of these applications, we feel are still very early in their adoption cycle. Yeah, we feel good about the long-term growth potential in that segment for that reason.
What about regionally, for that segment combined, is there any greater influence of China exposure, maybe either direct or indirect?
That's a good question. I think that there is an element of that. It has a little bit more China exposure than some of our other segments. We've never kind of broken that out, but it is fair to say that that's, you know, that there is a little bit more China exposure there.
Yeah. The other just reminder is that, you know, when we split out regional sales, it is shipped to locations. In other words, we could ship to a German OEM who then ships to China, right? You got to be a little bit cautious about correlating one to one what truly is the end market exposure.
Okay. Okay, that's helpful. Maybe just one last one. Any update on the legislation around smoke evacuation insufflators and anything we should be on the lookout for into the fall?
Yeah, listen, I think also there gradually there is continued adoption of the legislation of smoke evacuation in the U.S. as well as abroad. I think that trend overall is very positive. I think the additional trend that is positive is outside the legislation per se, how to integrate smoke evacuation as part of the workflow. We feel we have a very strong solution there, and that is basically confirmed by a very strong pool of multiple major customers. We see as a result that product category of ours you know driving strong adoption in the coming years, which was you know confirmed by design wins that we had last year.
We also see opportunity and we see convergence between basically laparoscopy and robotic surgery, so that smoke evacuation will play a stronger role there as well. We see multiple growth drivers, both you know, from a legislation perspective, product category, as well as adoption in new, you know, applications.
Okay. Thank you.
Thank you.
This concludes our question and answer session. I would like to turn the conference back over to Mr. Matthijs Glastra for any closing remarks.
Thank you, operator. To summarize, Novanta delivered very impressive results in the second quarter of 2022. We saw double-digit growth for sales, bookings, adjusted EBITDA, adjusted EPS, and we hit a new record high backlog. We achieved all of this while managing supply chain disruptions, rising costs, in a more uncertain, macro environment. We're excited to see the continued strength in the advanced industrial sector and also in the medical sector. Novanta is very well positioned in these sectors with diversified exposure to long-term secular macro trends in robotics and automation, precision medicine, minimally invasive surgery, and Industry 4.0. In closing, as always, I would like to thank our customers, our employees, and our shareholders for their ongoing support.
I continue to be especially grateful for the dedicated efforts of all our great Novanta employees who work so hard every day to tackle each new challenge. We appreciate your interest in the company and your participation in today's call. I look forward to joining all of you in several months on our third quarter 2022 earnings call. Thank you very much. This call is now adjourned.
The conference is now concluded. Thank you for attending today's presentation, and you may now disconnect.